

Special Issue

Advances in Clinical Trials and Precision Medicine for Neuro-Oncology

Message from the Guest Editor

Molecularly targeted therapies have transformed clinical outcomes in many solid tumours; however, until recently neuro-oncology treatment paradigms have been largely unchanged. Recent approvals for pan-cancer indications targeting *BRAF*V600E and evidence of efficacy of the IDH inhibitor vorasidenib have shed new light on the potential of molecularly targeted approaches for brain tumours. At the same time, risks associated with invasive procedures in the brain, the blood–brain barrier and difficulties in response assessment pose additional challenges in neuro-oncology compared to other tumour types, necessitating novel clinical trial paradigms to progress the field. This Special Issue focusses upon emerging molecular targets in neuro-oncology and novel clinical trial designs that may eventually translate to better clinical outcomes.

Guest Editor

Dr. Malaka Ameratunga

Medical Oncology Group of Australia, Monash University, Melbourne, VIC, Australia

Deadline for manuscript submissions

30 September 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/256638

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)